Schedule of Collaboration Agreements (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Disaggregation of Revenue [Line Items]  
Total $ 53,220
Development [Member]  
Disaggregation of Revenue [Line Items]  
Total 500 [1]
Reimbursements [Member]  
Disaggregation of Revenue [Line Items]  
Total 2,220 [2]
Unfront [Member]  
Disaggregation of Revenue [Line Items]  
Total 50,500 [3]
Immunomic Therapeutics [Member]  
Disaggregation of Revenue [Line Items]  
Total 3,220 [4]
Immunomic Therapeutics [Member] | Upfront [Member]  
Disaggregation of Revenue [Line Items]  
Total 500 [3],[4]
Immunomic Therapeutics [Member] | Development [Member]  
Disaggregation of Revenue [Line Items]  
Total 500 [1],[4]
Immunomic Therapeutics [Member] | Reimbursements [Member]  
Disaggregation of Revenue [Line Items]  
Total 2,220 [2],[4]
Roche [Member]  
Disaggregation of Revenue [Line Items]  
Total 50,000 [5]
Roche [Member] | Upfront [Member]  
Disaggregation of Revenue [Line Items]  
Total 50,000 [3],[5]
Roche [Member] | Development [Member]  
Disaggregation of Revenue [Line Items]  
Total [1],[5]
Roche [Member] | Reimbursements [Member]  
Disaggregation of Revenue [Line Items]  
Total [2],[5]
[1] Event-based development and regulatory milestones amounts.
[2] Reimbursements and costs-sharing payments.
[3] Upfront license fees.
[4] Regarding the accounting treatment for the collaborative agreement, the license and related development deliverables were determined to be highly interdependent and interrelated and have been combined as one performance obligation. Delivery is determined to be over time and revenue will be recognized utilizing an input method of costs incurred over total estimated costs in the work plan. The regulatory milestones are variable consideration that are fully constrained until the uncertainty of each milestone has been resolved. Sales-based milestones and royalties are variable consideration that will not be included in the transaction price until the related commercialization and sales have occurred. The cost reimbursements are considered variable consideration and are included in the transaction price. Revenues related to the cost reimbursements are presented gross on the consolidated statement of operations instead of a reduction to the costs being reimbursed. We currently estimate the unsatisfied performance obligations within the contract to be completed by December 31, 2022.
[5] Regarding the accounting treatment for the collaborative agreement, the license, technology transfer and related clinical deliverables were determined to be highly interdependent and interrelated and have been combined as one performance obligation. Delivery is determined to be over time and revenue will be recognized utilizing an input method of costs incurred over total estimated costs to complete the performance obligation. A material customer option for additional goods and services was included in the transaction price, and $12.0 million of the transaction price was allocated to the second performance obligation. The option will be recognized when the customer exercises the option or when the option expires. Regulatory and development milestones are variable consideration that are fully constrained until the uncertainty of each milestone has been resolved. Sales-based milestones and royalties are variable consideration that will not be included in the transaction price until the related commercialization milestones and sales targets have occurred. We currently estimate the unsatisfied performance obligations within the contract to be completed by December 31, 2026.